PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

PainReform Ltd.

PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, applying unique technologies for prolonged efficacy and reduced adverse effects.

COM:PAINREFORM

PainReform

Last Close

3.20

22/11 21:00

Market Cap

1.21M

Beta: -

Volume Today

439.35K

Avg: -